Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001123292-22-000014
Filing Date
2022-02-10
Accepted
2022-02-10 16:51:27
Documents
3

Document Format Files

Seq Description Document Type Size
1 allogene13ga.htm SC 13G/A 68800
2 image2.jpg GRAPHIC 40730
3 image3.jpg GRAPHIC 32519
  Complete submission text file 0001123292-22-000014.txt   171117
Mailing Address 333 LAKESIDE DR FOSTER CITY CA 94404
Business Address 333 LAKESIDE DR FOSTER CITY CA 94404 6505743000
GILEAD SCIENCES INC (Filed by) CIK: 0000882095 (see all company filings)

EIN.: 943047598 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90685 | Film No.: 22614896
SIC: 2836 Biological Products, (No Diagnostic Substances)